Am J Transplant, Volume 16, Suppl 3 Archives - Page 116 of 180 - ATC Abstracts

2016 American Transplant Congress
Rapid Emergence of CD28^null Cells Following Ex Vivo Restimulation Is Associated with Belatacept Resistant Rejection.
M. Cortes, S. Laurie, B. Sayed, M. Ford.
Emory Transplant Center, Atlanta, GA.
Numerous studies have implicated donor-reactive memory T cells in mediating costimulation blockade resistant rejection (CoBRR) following treatment with belatacept. In humans, these memory T cells…
2016 American Transplant Congress
The Impact of Treating Borderline Cellular Rejections.
R. Mustafa,¹ Y. Al Azzi,¹ J. Crew,¹ G. Dube,¹ H. Morris,¹ M. Chiles,¹ J. Chang,¹ H. Fernandez,¹ D. Cohen,¹ I. Batal,² E. Campenot,² S. Mohan.¹
¹Nephrology, Columbia University Medical Center, New York, NY; ²Pathology, Columbia University Medical Center, New York, NY.
Introduction: Histological findings that meet the criteria for Borderline rejection (BR) as defined by the Banff Classification are frequently seen. The clinical significance of a…
2016 American Transplant Congress
3D-FLM (First, Last, Max): A Novel Summative Measure of Hepatocellular Carcinoma (HCC) Tumor Burden Predicts HCC Recurrence After Liver Transplantation (LT).
E. Nordstrom,¹ J. Dodge,² J. Gralla,¹ K. Campbell,¹ C. Palmer,¹ S. Biggins.¹
¹Univ. Colorado, Aurora; ²UCSF, San Francisco.
Risk of recurrent HCC post-LT depends on tumor aggressiveness, pre-LT HCC burden and treatment response while waiting for LT. Standard measures of pre-LT HCC burden…
2016 American Transplant Congress
Minimum Graft Size Avoiding Small-for-Size Associated Early Graft Failure in Living Donor Liver Transplantation.
S. Marubashi,¹ H. Nagano,³ H. Eguchi,² H. Wada,² K. Umeshita,² Y. Doki,² M. Mori,² N. Sato,¹ T. Kimura,¹ A. Kenjyo,¹ M. Gotoh.¹
¹Regenerative Surgery, Fukushima Medical University, Fukushima, Japan; ²Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Small-for-size syndrome (SFSS) is a serious complication in living donor liver transplantation (LDLT). The aim of this study was to investigate the risk factors for…
2016 American Transplant Congress
Longitudinal Psychological Outcomes of Living Liver Donors.
Z. Butt,¹ M. Dew,² Q. Liu,³ M. Simpson,⁴ A. Smith,^3,5 J. Zee,³ B. Gillespie,⁵ S. Abbey,⁶ D. Ladner,¹ R. Weinreib,⁷ R. Fisher,⁸ S. Hafliger,⁹ N. Terrault,¹⁰ J. Burton,¹¹ A. DiMartini.²
¹Northwestern U, Chicago; ²U of Pittsburgh, Pittsburgh; ³Arbor Research Collaborative for Health, Ann Arbor; ⁴Lahey, Burlington; ⁵U of Michigan, Ann Arbor; ⁶U of Toronto, Toronto, Canada; ⁷U of Pennsylvania, Philadelphia; ⁸Virginia Commonwealth U, Richmond; ⁹Columbia U, New York; ¹⁰U of California at San Francisco, San Francisco; ¹¹U of Colorado, Denver.
Background: Living liver donors (LLD) are healthy adults donating a portion of their liver to a recipient in need. To justify the risk to LLD,…
2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
¹Houston Methodist Hospital, Houston, TX; ²Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneﬁcial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
2016 American Transplant Congress
Is Ketorolac Really Safe for Donor Nephrectomy?
K. Takahashi, K. Putchakayala, L. Malinzak, J. Denny, M. Abouljoud, D. Kim.
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI.
Background. Ketorolac is a nonsteroidal anti-inflammatory drug used for postoperative pain management. The purpose of this study is to assess the impact of ketorolac after…
2016 American Transplant Congress
Clinical Outcome on Kidney Retransplantation in Comparison with First Kidney Transplantation in Korea – Nationwide Cohort Study.
J. Kim,^1,2 T. Ban,^1,2 B. Jung,^1,2 B. Choi,^1,2 C. Park,^1,2 C. Yang,^1,2 Y.-S. Kim.^1,2
¹Transplantation Research Center, Seoul St. Mary's Hospital, Seoul, Republic of Korea; ²Internal Medicine, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
Due to the limitation of the survival of kidney allograft, increasing number of patients need to take re-transplantation (re-KT) after the first allograft failure. In…
2016 American Transplant Congress
Urinary Markers of Proximal Tubular Dysfunction in Kidney Transplant as Predictors for CKD.
P. Garcia, V. Garcia-Nieto, J. Navarro, E. Martin, A. Rivero, A. Jarque, J. Gonzalez-Posadas, M. Macia.
Nephrology, Universitary NTRA.SRA.Candelaria Hospital, SC Tenerife, Spain.
AIMS:Analyze urinary markers of proximal tubular dysfunction (PTD)(b2 microglobulin (b2m),N-acetyl-glucosaminidase (NAG) and Clara Cell Protein (CC16)) in kidney transplant (KT) patients, compared with a healthy…
2016 American Transplant Congress
Living Related Small Bowel Transplantation in Children, a Single-Center Experience – Growth, Development and Quality of Life 10 Years After Transplant.
S. Garcia Aroz,¹ I. Tzvetanov,¹ E. Hetterman,² J. Hoonbae,¹ M. Spaggiari,¹ J. Oberholzer,¹ G. Testa,³ E. John,⁴ E. Benedetti.¹
¹Surgery, University of Illinois, Chicago, IL; ²Pharmacy, University of Illinois, Chivago, IL; ³Surgery, Baylor Medical Center, Dallas, TX; ⁴Pediatrics, University of Illinois, Chicago, IL.
Summary Background: Pediatric patients with irreversible intestinal failure present multiple challenges due to their young ages and their associated growth needs. We have previously published…